Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

CLICK HERE FOR CME CREDIT

Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Michael J. Blaha, MD, MPH

Michael J. Blaha, MD, MPH

Director of Clinical Research Ciccarone Center for the Prevention of Heart Disease

Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Associate Professor of Medicine
Johns Hopkins School of Medicine
Baltimore, MD